NCT03079687 2017-10-25Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.AstraZenecaApproved for marketing
NCT03025867 2017-04-17Expanded Access Protocol for Niraparib in Patients With Recurrent Ovarian CancerTesaro, Inc.Approved for marketing